All In Biotech

Drug Trial Radar · NCT03810664

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

A Phase 1, Single-Center, Randomized, Cross-Over, Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

Last checked: Nov 20, 2026Latest source record: Apr 28, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Jan 18, 2019

Primary completion

Apr 19, 2019

Study completion Apr 19, 2019

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Jan 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single-center, open-label randomized, 2×2 crossover (Ref Test \| Test Ref) study with a washout of two weeks to establish bioequivalence between single dose of somatrogon in a PEN to somatrogon in VIAL administered sc in healthy male volunteers.

Conditions

  • Healthy Male Volunteers

Interventions

  • SomatrogonDrug

    A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the curve (AUC) of the serum concentration-time from time 0 to a specific time (AUCt)Time frame: 30 days
  2. Area under the curve (AUC) of the serum concentration-time from time 0 to infinity (AUC∞)Time frame: 30 days
  3. Serum concentration from of maximum concentration (Cmax) of somatrogon levels in serumTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QPS Miami Research Associates

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.